These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23354848)

  • 1. Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas.
    Dasgupta T; Haas-Kogan DA; Yang X; Olow A; Yang DX; Gragg A; Orloff LA; Yom SS
    Invest New Drugs; 2013 Oct; 31(5):1136-41. PubMed ID: 23354848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
    Dasgupta T; Olow AK; Yang X; Hashizume R; Nicolaides TP; Tom M; Aoki Y; Berger MS; Weiss WA; Stalpers LJ; Prados M; James CD; Mueller S; Haas-Kogan DA
    J Neurooncol; 2016 Feb; 126(3):385-93. PubMed ID: 26384810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Combinatorial Strategy for Targeting
    Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E
    Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined BRAF
    Zhang J; Yao TW; Hashizume R; Hariono S; Barkovich KJ; Fan QW; Prados M; James CD; Weiss WA; Nicolaides T
    J Neurooncol; 2017 Feb; 131(3):495-505. PubMed ID: 27848137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
    Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
    Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
    Salerno P; De Falco V; Tamburrino A; Nappi TC; Vecchio G; Schweppe RE; Bollag G; Santoro M; Salvatore G
    J Clin Endocrinol Metab; 2010 Jan; 95(1):450-5. PubMed ID: 19880792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.
    Oikonomou E; Koc M; Sourkova V; Andera L; Pintzas A
    PLoS One; 2011; 6(6):e21632. PubMed ID: 21738740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.
    Roulstone V; Pedersen M; Kyula J; Mansfield D; Khan AA; McEntee G; Wilkinson M; Karapanagiotou E; Coffey M; Marais R; Jebar A; Errington-Mais F; Melcher A; Vile R; Pandha H; McLaughlin M; Harrington KJ
    Mol Ther; 2015 May; 23(5):931-942. PubMed ID: 25619724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.
    Mitsiades N; Chew SA; He B; Riechardt AI; Karadedou T; Kotoula V; Poulaki V
    Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7248-55. PubMed ID: 21828154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
    Tsai J; Lee JT; Wang W; Zhang J; Cho H; Mamo S; Bremer R; Gillette S; Kong J; Haass NK; Sproesser K; Li L; Smalley KS; Fong D; Zhu YL; Marimuthu A; Nguyen H; Lam B; Liu J; Cheung I; Rice J; Suzuki Y; Luu C; Settachatgul C; Shellooe R; Cantwell J; Kim SH; Schlessinger J; Zhang KY; West BL; Powell B; Habets G; Zhang C; Ibrahim PN; Hirth P; Artis DR; Herlyn M; Bollag G
    Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3041-6. PubMed ID: 18287029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
    Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA
    Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
    Liu R; Liu D; Xing M
    J Clin Endocrinol Metab; 2012 Feb; 97(2):E173-82. PubMed ID: 22090271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
    Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
    Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
    Knight DA; Ngiow SF; Li M; Parmenter T; Mok S; Cass A; Haynes NM; Kinross K; Yagita H; Koya RC; Graeber TG; Ribas A; McArthur GA; Smyth MJ
    J Clin Invest; 2013 Mar; 123(3):1371-81. PubMed ID: 23454771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.
    Zhang J; Lu B; Liu D; Shen R; Yan Y; Yang L; Zhang M; Zhang L; Cao G; Cao H; Fu B; Gong A; Sun Q; Wan H; Zhang L; Tao W; Cao J
    Cancer Biol Ther; 2016; 17(2):199-207. PubMed ID: 26810733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
    McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC
    J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
    Walter L; Heinzerling L
    Anticancer Res; 2018 Mar; 38(3):1335-1341. PubMed ID: 29491057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
    Joshi M; Rice SJ; Liu X; Miller B; Belani CP
    PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.
    Yuan P; Ito K; Perez-Lorenzo R; Del Guzzo C; Lee JH; Shen CH; Bosenberg MW; McMahon M; Cantley LC; Zheng B
    Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18226-31. PubMed ID: 24145418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
    Chakravarty D; Santos E; Ryder M; Knauf JA; Liao XH; West BL; Bollag G; Kolesnick R; Thin TH; Rosen N; Zanzonico P; Larson SM; Refetoff S; Ghossein R; Fagin JA
    J Clin Invest; 2011 Dec; 121(12):4700-11. PubMed ID: 22105174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.